Harmony Biosciences Holdings Inc [HRMY] stock is trading at $39.05, up 1.32%. An important factor to consider is whether the stock is rising or falling in short-term value. The HRMY shares have gain 15.33% over the last week, with a monthly amount glided 18.12%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Harmony Biosciences Holdings Inc [NASDAQ: HRMY] stock has seen the most recent analyst activity on December 17, 2024, when H.C. Wainwright initiated its Buy rating and assigned the stock a price target of $75. On September 10, 2024, UBS initiated with a Buy rating and assigned a price target of $56 on the stock. Citigroup started tracking the stock assigning a Buy rating and suggested a price target of $48 on June 21, 2024. BofA Securities downgraded its rating to a Underperform but $30 remained the price target by the analyst firm on January 02, 2024. Goldman downgraded its rating to Sell for this stock on September 25, 2023, and downed its price target to $31. In a note dated September 07, 2023, Berenberg initiated an Buy rating and provided a target price of $59 on this stock.
Harmony Biosciences Holdings Inc [HRMY] stock has fluctuated between $28.14 and $41.61 over the past year. Currently, Wall Street analysts expect the stock to reach $45.33 within the next 12 months. Harmony Biosciences Holdings Inc [NASDAQ: HRMY] shares were valued at $39.05 at the most recent close of the market. An investor can expect a potential return of 16.08% based on the average HRMY price forecast.
Analyzing the HRMY fundamentals
Harmony Biosciences Holdings Inc [NASDAQ:HRMY] reported sales of 681.88M for the trailing twelve months, which represents a growth of 16.08%. Gross Profit Margin for this corporation currently stands at 0.77% with Operating Profit Margin at 0.26%, Pretax Profit Margin comes in at 0.26%, and Net Profit Margin reading is 0.18%. To continue investigating profitability, this company’s Return on Assets is posted at 0.13, Equity is 0.23 and Total Capital is 0.23. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.31.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 38.52 points at the first support level, and at 37.99 for the second support level. However, for the 1st resistance point, the stock is sitting at 39.56, and for the 2nd resistance point, it is at 40.08.
Ratios To Look Out For
For context, Harmony Biosciences Holdings Inc’s Current Ratio is 3.24. On the other hand, the Quick Ratio is 3.20, and the Cash Ratio is 2.4. Considering the valuation of this stock, the price to sales ratio is 3.27, the price to book ratio is 3.73 and price to earnings (TTM) ratio is 18.49.
Transactions by insiders
Recent insider trading involved Dierks Jeffrey, CHIEF COMMERCIAL OFFICER, that happened on Jan 15 ’25 when 10507.0 shares were sold. CHIEF COMMERCIAL OFFICER, Dierks Jeffrey completed a deal on Jan 13 ’25 to sell 7180.0 shares. Meanwhile, Officer JEFFREY G DIERKS bought 47162.0 shares on Jan 13 ’25.
